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Prevalence and risk factors for hepatitis B virus
infections among visitors to an STD clinic
Y T H P van Duynhoven, M JW van de Laar, W A Schop, Ph H Rothbarth,
W I van der Meijden, A M van Loon, M JW Sprenger
Objective: To determine the prevalence and risk factors for hepatitis B virus (HBV) infections
among individuals attending an STD clinic in a low endemic region.
Study design: A total of 1228 women and 1648 men attending the STD clinic at the University
Hospital Rotterdam, Netherlands, were examined for HBV infection by determination of hepati-
tis B surface antigen (HBsAg) and antibodies to hepatitis B core antigen (anti-HBc).
Demographic characteristics, information on sexual behaviour, and intravenous drug use were
recorded.
Results: The seroprevalence of HBsAg was 1.4% in women and 2 1% in men (0% in homosex-
ual men). The seroprevalence of anti-HBc was 13% in women and 20% in men (36% in homo-
sexual men). Native country, intravenous drug use, a history of STD, and the number of
partners in the past half year (inversely) were independent risk factors for HBsAg positivity in
women and heterosexual men. For anti-HBc independent associations were observed for native
country, age, intravenous drug use, commercial sex, number of lifetime partners, homosexual
contacts, orogenital contact (inverse), and a history of STD.
Conclusion: The HBV prevalence in the STD clinic attendants was high, exceeding the
national estimate, and indicates that the STD clinic population may be considered a high risk
group. Our data confirmed an increased risk for HBV infections among established risk groups.
Therefore, these risk groups should be routinely screened to identify HBV cases for counselling
and contact tracing.
(Genitourin Med 1997;73:488-492)
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Introduction
In low endemic regions infections with hepati-
tis B virus (HBV) occur predominantly in
adults, largely as a result of sexual contact and
parenteral transmission.' 2 About 5%-10% of
the population will experience infection during
their lifetime and less than 1% of adults are
HBV carriers.' In the Netherlands the esti-
mated prevalence for HBsAg is 0.4%, based
on a screening programme for pregnant
women.3 Like in other parts of Europe, the
number of notified cases has declined consid-
erably since the mid 1980s.45 This was mainly
caused by reduction of risk behaviour and is
only partially attributable to the effect of vacci-
nation against hepatitis B.4 At present, the
control of HBV infections in the Netherlands
includes counselling and contact tracing of
HBV cases to prevent further transmission,
targeted vaccination of high risk groups, and
immunisation of children born to HBsAg
positive mothers detected through a screening
programme for pregnant women.36 Imple-
mentation of universal hepatitis B vaccination
into the Dutch immunisation programme is
now under debate.7
In the Netherlands, the prevalence and cor-
relates ofHBV infection in STD clinic popula-
tions were seldom documented because
screening on HBV is not routine in these clin-
ics. In 1994 a cross sectional study was carried
out at the STD clinic of the University
Hospital Rotterdam, which is the only STD
clinic in the Netherlands with an ongoing uni-
versal screening for HBV. The objective of the
current study was (1) to assess the HBV preva-
lence among STD clinic attendants and (2) to
identify risk factors for HBV infection in this
population.
Patients and methods
STUDY POPULATION
In 1994 a cross sectional study was carried out
among visitors to the STD clinic of the
Department of Dermatology and Venereology,
at the University Hospital of Rotterdam. The
following items were recorded on standardised
forms: reason for visiting the clinic, specific
urogenital complaints, and former experiences
with STD; for women additional information
was collected on their menstrual cycle and
reproductive history. In addition, attendants
were asked about age at first sexual inter-
course, sex of sexual contacts, type (steady,
casual, commercial) and sex of last and former
sexual contact, the number of sexual partners
in three periods (past month, half year, and
lifetime), orogenital and anal contact in the
past 6 months, and condom use while having
intercourse with casual partners in the past 6
months. Also intravenous drug use (past 3
months, ever, or never) and either work as a
prostitute or visit to a prostitute (past 3
months, ever, or never) was reported. Finally,
participants were questioned about national-
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ity, native country, and use of antibiotics in
the preceding 4 weeks. No information was
collected on hepatitis specific complaints, vac-
cination status, and parenteral transmission
routes other than intravenous drug use.
LABORATORY TESTING
From all visitors, blood samples were taken
routinely for determination of (past) HBV
infection. Assays included those for hepatitis B
surface antigen (HBsAg) (MEIA, Abbott,
Chicago, IL, USA) and for total antibodies to
hepatitis B core antigen (anti-HBc) (MEIA)
and were carried out at the Department of
Virology, University Hospital Rotterdam.
HBsAg positive results were confirmed either
by a passive haemagglutination assay
(Hepatest, Murex, Dartford) or a neutralisa-
tion MEIA (Abbott, Chicago, IL, USA) if the
passive haemagglutination test was inconclu-
sive. After confirmation of a positive HBsAg,
further MEIAs were performed for determina-
tion of antibodies to hepatitis B e antigen
(anti-HBe) and for hepatitis B e antigen
(HBeAg) (Abbott, Chicago, IL, USA). Sera
which tested negative for HBsAg and positive
for anti-HBc were tested for antibodies to
hepatitis B surface antigen (anti-HBs)
(MEIA). If sera were only positive for anti-
HBc, additional tests for HBeAg and anti-HBe
were to exclude a window phase after a recent
infection.
STATISTICAL ANALYSES
Univariate analyses for HBsAg positivity and
anti-HBc positivity were carried out, com-
bined for men and women, by using the x2 test
or the two tailed Fisher exact test. Relevant
associations with a p value of 0.10 or less were
further analysed by multiple logistic regression
analysis to correct for confounding variables
and to evaluate possible effect modification.
Sex was always included in the model. A full
model, including the main effects of the uni-
variate analysis, was compared with models
excluding every other factor. A factor
remained in the model if either the likelihood
ratio test was significant (p < 0.05) or the esti-
mates of the P coefficients for other variables
in the model changed by at least 10%. Odds
ratios (OR) are presented with 95% confi-
dence intervals (CI).
Table 1 Prevalence ofHBsAg and anti-HBc among 2876 visitors of the STD clinic,
University Hospital Rotterdam, 1994, by sex
HBsAg positive Anti-HBc positive
n % n %
Men n = 1648 35* 2-1 322t 19-5
Women n = 1228 17t 1-4 160§ 13-0
Total n = 2876 52 1-8 482 16.8
*33 men were HBsAg, anti-HBc, and anti-HBe positive, one man was HBsAg, HBeAg, and anti-
HBc positive, and the remaining man was only HBsAg positive (serology of other HBV markers
incomplete).
t15 women were HBsAg, anti-HBc, and anti-HBe positive and the remaining two women were
HBsAg, HBeAg, and anti-HBc positive.
*For 34 of these men see above* regarding HBsAg, for the remainder: 269 men were both anti-
HBc and anti-HBs positive, five men were anti-HBc and anti-HBe positive but anti-HBs
negative, the remaining 14 men were only anti-HBc positive (for eight of them serology of other
HBV markers was incomplete).
§For 17 of these women see abovet regarding HBsAg, for the remainder: 131 women were both
anti-HBc and anti-HBs positive, six women were anti-HBc and anti-HBe positive but anti-HBs
negative and the remaining six women were only anti-HBc positive (for four of them serology of
HBV markers was incomplete).
Results
PATIENT POPULATION
Of the eligible population of 3277 individuals,
1696 men and 1288 women (2984 in total)
were tested for at least one STD and were
available for analyses (91%). The remaining
9% were very similar to the study participants,
although non-participants were born in the
Netherlands more often and reported a history
of STD as well as drug use and commercial
sex contacts less often (data not shown). The
mean age for men was 34'3 years and for
women 29-7 years. About 60% were born in
the Netherlands. Sixty three per cent of the
men and 47% of the women presented at the
clinic with urogenital symptoms. Of the
women, an additional 10% attended the clinic
because of the urogenital complaints of their
sexual partners. About two thirds of the visi-
tors were self referred, 18% of men and 12%
ofwomen were referred by their general practi-
tioner, and 4% of men and 5% ofwomen by a
specialist doctor.
PREVALENCE OF HBV MARKERS
In all, 2876 (96%) serum samples were exam-
ined for HBV infection. HBsAg was found in
the blood of 17 (1.4%) women and 35 (2-1%)
men (table 1). Of these, two women and one
man were also HBeAg positive. Four men
were known HBsAg carriers. In addition, 160
women (13-0%) and 322 men (19-5%) were
anti-HBc positive, indicating past HBV infec-
tion.
RISK FACTORS FOR HBSAG POSITIVITY AND
ANTI-HBC
No association between HBsAg positivity and
age or sex was found, but anti-HBc was higher
in men and increased steadily with age (table
2). Very strong associations were found for
native country. Both HBsAg and anti-HBc
were more prevalent among visitors born in
Surinam, Morocco, or Turkey and particularly
among the relatively small group from Cape
Verde. The remaining foreign born visitors
(about 85% born in high and middle endemic
regions such as sub-Saharan Africa, Asia,
Dutch Antilles, Middle/South America, east-
ern Europe, and Mediterranean countries)
were also at increased risk for positive HBV
markers. Individuals currently using intra-
venous drugs were also more often HBsAg
positive or anti-HBc positive. For anti-HBc
this also accounted for those with a history of
drug use.
HBsAg was not observed among homosexu-
als (compared with 1.9% for heterosexuals
and 3*1% for bisexuals). However, the anti-
HBc prevalence of 35.8% was the highest for
this group compared with 14.9% among het-
erosexuals and 26% for bisexuals. Individuals
reporting commercial sex (work or visit)
tended to have a high HBsAg and anti-HBc
prevalence, but even higher rates were found
among those without information on commer-
cial sex (table 2). An inverse relation for
HBsAg with the number of partners in the
past half year was suggested, although this
trend was not statistically significant. Anti-
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Table 2 Univariate analyses ofpatient characteristics for HBsAg positivity and anti-HBc positivity among 2876 visitors of the STD clinic, University
Hospital Rotterdam, 1994
Patient characteristics Number' HBsAg OR HBsAg anti-HBc OR anti-HBc
Total 2876 1.8% 95% CI 16.8% 95% CI
Sex: *
Men 1648 2-1 1-5 (0.9-2.8) 19.5 1-6 (1-3-2-0)
Women 1228 1.4 1-0 13.0 1-0
Age (years):*
11-19 187 0.0 - 6-4 0-6 (0-3-1-1)
20-24 531 1-7 1-0 10-9 1-0
25-29 664 2-0 1-2 (0.5-2.7) 13-3 1-2 (0-9-1-8)
30-34 583 2-4 1-4 (0.6-3.3) 16-6 1-6 (1 1-2 3)
> 35 911 1-8 1.0 (0.5-2.4) 24-9 2-7 (2 0-3.7)
Native country:
Netherlands 1701 0.4 1-0 8-9 1-0
Surinam/Morocco/Turkey 566 4-1 10-6 (4.5-24.8) 22-4 3-4 (2.7-4.3)
Cap Verde 66 9-1 25-0 (8-1-76.6) 47.0 8-4 (5.1-14-0)
Other countries 488 3-3 8-5 (3 5-20.7) 27-7 3-6 (2.8-4.7)
Intravenous drug use:
Never 2406 1-6 1-0 15-3 1-0
Past 3 months 108 4-6 2-9 (1-1-7-6) 39-8 3-7 (255-55)
Ever (> 3 months ago) 98 1.0 0-6 (0-1-4-6) 32-7 2-7 (1-7-4-2)
Unknown 264 2-7 1-7 (0.7-3.7) 15-2 1-0 (0-7-1-4)
Commercial sex (work or visit): **
Never 1806 1-3 1-0 13-2 1-0
Past3months 400 2-3 1-8 (1-0-3-3) 21-3 1-9 (1-6-2-4)
Ever (> 3 months ago) 510 2-6 T 23-7 1
Unknown 160 3-8 2-9 (1-2-7-2) 23-1 2-0 (1-3-2-9)
Number of partners past half year: **
0 136 4-4 22 (09-54) 19-9 15 (09-23)
1 1356 2-1 1-0 14-5 1.0
2 685 1.0 0.5 (0.2-1-1) 13-6 0.9 (0-7-1-2)
3 542 1-9 09 (0-4-1.8) 23-4 1-8 (14-2-3)
Unknown 157 0-6 0.3 (0.04-2.3) 24-8 2-0 (1-3-2-9)
Condom casual partners past half year: ***2 *
Never, sometimes, half the times 740 2-3 2-6 (1-0-6-5) 19-2 1-0 (0-7-1-3)
Mostly (60-95%) or always 657 0-9 1-0 18-6 1-0
No casual partners reported 1315 2-1 2-3 (0.9-5.5) 14-4 0.7 (0.5-0.9)
Unknown 164 1-2 1-3 (0.3-6.7) 17-7 0.9 (0-6-1-4)
Orogenital contact in past half year:
No 1167 2.9 1.0 20.4 1.0
Yes 1552 1-2 0.4 (0.2-0.8) 13.5 0-6 (0.5-0.7)
History of STD:**
No 1601 1.1 1-0 12-9 1-0
Yes 1247 2-7 2-5 (1-4-4-4) 21-7 19 (1-5-2-3)
*** = P < 0-05, ** = P < 0- 10, * = P > 0 10 for either X' or Fisher exact test.
'Totals do not always add to this number because of missing values.
2The x2 test was restricted to those with casual partners and information on condom use.
Table 3 Multiple logistic regression analyses for HBsAg and anti-HBc among 2876
visitors of the STD clinic, University Hospital Rotterdam, 1994
HBsAg' adjusted
OR (95% CI)
Demographic characteristics
Sex:
Men
Women
Age (years):
11-19
20-24
25-29
30-34
35
Native country:
Netherlands
Surinam/Morocco/Turkey
Cape Verde
Other countries
(Intravenous) drug use:
Never
Past 3 months
Ever (> 3 months ago)
Unknown
Sexual characteristics
Sex of sexual partners past year:
Heterosexual contacts only
Homo- and hetero contacts
Homosexual contacts only
Number of partners:
HBsAg: 0 anti-HBc: 1-5
half year 1 lifetime 6-10
2 11-20
3 >20
Unknown Unknown
Commercial sex (work or visit):
Never
Past 3 months or ever
Unknown
Orogenital contact in past half year:
No
Yes
History of STD:
No
Yes
1.9 (1.0-3.6)
1-0
not in the model
1-0
10-9 (4.5-26.2)
26-2 (8.2-84.2)
9-1 (3.7-22.7)
1-0
4-1 (1-5-11-4)
0.7 (0.1-5.1)
2-5 (1.0-6.2)
not in the model
2-7 (1 0-7.0)
1-0
0.4 (0.2-0.8)
0-6 (0-3-1-4)
0-2 (0-03-1-4)
not in the model
not in the model
1-0
2-5 (1A-445)
anti-HBc2 adjusted
OR (95% CI)
1-0 (0-8-1-3)
1-0
0-5 (0.3-1.1)
1-0
1-1 (0.8-1-7)
1-5 (1.0-2-3)
2-3 (1-6-3-3)
1-0
5-2 (3-8-7-0)
14-1 (8.1-24-6)
4-8 (3.6-6.4)
1-0
4-8 (3-0-7-8)
3-7 (2.3-6.1)
1-2 (0.8-1-9)
1-0
2-5 (1-4-4-2)
6-9 (4.5-10-4)
1-0
0-6 (04-0-8)
2-1 (0.7-6-0)
1-8 (1.1-3-1)
1-0 (0-6-1-6)
1-0
1-3 (10-1-8)
1.4 (0-8-2-3)
1-0
0-7 (0-5-0-9)
1-0
1-4 (1-117)
HBc was found more often among those with
three or more sexual partners in the past half
year. The same was found when the number
of partners in the past month or during life-
time (more than 10) was considered (data not
shown). Use of condoms in less than 60% of
casual contacts in the past half year was associ-
ated with HBsAg positivity compared with
more frequent use of condoms, but no associa-
tion with anti-HBc was found (table 2). For
both HBV markers a protective effect was
found for orogenital contact in the past half
year. A history of STD was associated with a
higher prevalence of HBsAg and anti-HBc.
Finally, no associations with HBsAg were
found for age at first sexual intercourse, a
steady relationship, the type of partner during
last and former sexual contact, anal contact in
the past 6 months, and the number of partners
in the past month and during lifetime. For
anti-HBc no relevant associations were
observed for age at first sexual intercourse, a
steady relationship, and the type of partner
during last and former sexual contact.
MULTIPLE LOGISTIC REGRESSION
For HBsAg homosexuals were excluded from
the multiple regression analyses. The final
logistic model included (table 3) sex, native
country, intravenous drug use, the number of
partners in the past half year, and a history of
STD. The ORs were very similar to those
found in the univariate analyses (including the
homosexuals), with the exception of a rise in
the OR for recent drug use from 2.9 to 4d1.
1174 homosexual men excluded (HBsAg prevalence was 0% in this group) -2 log likelihood
presented model (n = 2663, %HBsAg = 2 0): 427-1, df = 12, p = 0.0001.
2-2 log likelihood presented model (n = 2774, %anti-HBc = 16-6): 2032-8, df= 19, p = 0-0001.
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This was mainly due to correction for native
country; because 8% of the Dutch visitors
reported drug use, compared with 1% to 4%
of the (highly infected) foreign born visitors,
Dutch were overrepresented among the intra-
venous drug users.
For anti-HBc all risk factors were kept in
the model (table 3). However, sex was no
longer associated with anti-HBc after adjust-
ment for the effect of other risk factors. All the
ORs increased except for sex, commercial sex-
ual contacts, and the history of STD. When
the number of lifetime partners was substi-
tuted for those in the past half year no associa-
tion with the number of partners was found.
Discussion
This study estimated the prevalence and iden-
tified risk factors for HBV infections among
STD clinic attendants. Both the seropreva-
lence of HBsAg and anti-HBc among atten-
dants of the STD clinic were high and
exceeded the estimated national prevalence of
0.4% for HBsAg and less than 10% for anti-
HBc."13Therefore, the STD clinic population
can be considered a high risk group for HBV
infections. The HBsAg rate of 1.8% is within
the range of the 0.2% and 5% found by oth-
ers.89 The prevalence of anti-HBc also corre-
spond well with other studies in similar
settings.8-'0 However, our HBsAg and anti-
HBc prevalences may be slightly underesti-
mated because vaccinated individuals could
not be identified and excluded from the
denominator. On the contrary, the low risk
character of the non-participants in this study
might have caused a minor overestimation of
the HBV prevalence.
Increased rates of HBV markers were
observed among individuals born in interme-
diate and high endemic countries and to a
lesser extent among intravenous drug users,
homosexuals, those with multiple partners or
commercial sexual contacts, or a history of
STD. The high prevalence for the ethnic
minorities was probably due to infection at
birth or early in life, as the most likely trans-
mission routes in these regions, with a higher
probability of developing to chronic asympto-
matic infection.'"1 Ethnic differences in the
prevalence of HBV markers were also noticed
in the STD clinic in Amsterdam,
Netherlands,'0 in an STD clinic in
Copenhagen, Denmark,'2 and in two STD
clinics in the West Midlands."3
Although the seroprevalence of HBsAg was
0% in homosexuals, the high anti-HBc rate
illustrated an increased risk for this group.
Absence of HBsAg could be due to chance or
may be explained by immunity as a result of
previous HBV infection, reduction of high risk
behaviour, and vaccination.
Our study demonstrated a negative associa-
tion for HBsAg and the number of partners in
the past half year, while in other studies posi-
tive associations were reported.2 This finding
may be due to confounding by non-measured
parenteral transmission routes. Also, the 6
month period for reported sexual activity
could be less appropriate for assessing relevant
exposure to HBV. None the less, the high anti-
HBc-rates among those with multiple partners
in addition to the high HBV prevalence among
individuals who suffered from an STD corre-
sponds well with others2 and suggests that sex-
ual transmission is of importance in this
population.
HBV infections at the STD clinic were
mainly observed among established risk
groups. Therefore, homosexual men, intra-
venous drug users, individuals with multiple
partners, individuals with commercial sexual
contacts, those with a history of STD, and
those born in endemic countries should be
routinely screened at STD clinics for case
finding. Counselling of the HBsAg positive
patient and tracing sexual and household con-
tacts should be performed routinely to inform
about the potential risk of HBV and to offer
vaccination if appropriate. If, at this clinic,
screening was restricted to the risk groups,
96% of the anti-HBc positives and 98% of the
HBsAg positives would have been detected.
However, as these risk groups already repre-
sented 76% of the total clinic population,
universal screening is recommended, corre-
sponding with the current policy.
The high prevalence, the apparent risk fac-
tors, and the large absolute number of high
risk individuals in the STD clinic population
in Rotterdam might suggest the potential of
STD clinics in reaching risk groups for
targeted vaccination, as earlier suggested
by United Kingdom data on STD clinic
attendance.'4 A more adequate vaccination
approach seems warranted by the current low
vaccination coverage for sexual partners of
HBsAg positive individuals, homosexual men,
prostitutes, and intravenous drug users in the
Netherlands.7 However, to determine the suit-
ability of STD clinics as places for HBV vacci-
nation, further studies are needed on HBV
incidence, STD clinic attendance of high risk
individuals, costs, and other aspects affecting
the success of vaccination.'5-'8
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